{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:12:16Z","timestamp":1790683936234,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,18]]},"DOI":"10.7759\/cureus.77641","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:12:57Z","timestamp":1737267177000},"source":"Crossref","is-referenced-by-count":3,"title":["Successful Treatment of Refractory Ulcerative Colitis With 5-Aminosalicylic Acid Intolerance and Biologic Therapy Resistance Using Combined Granulocyte and Monocyte Adsorptive Apheresis"],"prefix":"10.7759","author":[{"given":"Tomotaka","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syohei","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Arataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15138","article-title":"Multicenter survey on mesalamine intolerance in patients with ulcerative colitis","volume":"36","author":"Hiraoka S","year":"2021","unstructured":"Hiraoka S, Fujiwara A, Toyokawa T, et al.. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol. 2021, 36:137-43. 10.1111\/jgh.15138","journal-title":"J Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet L","year":"2019","unstructured":"Peyrin-Biroulet L, Danese S, Argollo M, et al.. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019, 17:838-846.e2. 10.1016\/j.cgh.2018.06.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh S","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018, 12:635-43. 10.1093\/ecco-jcc\/jjy004","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3862\/jcoloproctology.67.259","article-title":"Desensitization therapy for mesalazine-intolerant patients with inflammatory bowel disease (Article in Japanese)","volume":"67","author":"Fukushima T","year":"2014","unstructured":"Fukushima T, Nakajima K, Henmi H, et al.. Desensitization therapy for mesalazine-intolerant patients with inflammatory bowel disease (Article in Japanese). J Jpn Colonproctol. 2014, 67:259-62. 10.3862\/jcoloproctology.67.259","journal-title":"J Jpn Colonproctol"},{"key":"ref5","article-title":"Mesalamine tolerance of ulcerative colitis","volume":"4","author":"Motoya S","unstructured":"Motoya S, Shimodate Y, Tanaka H, et al.. Mesalamine tolerance of ulcerative colitis. IBD Res. 4:127-131.","journal-title":"IBD Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i13.3716","article-title":"Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity","volume":"20","author":"Ding H","year":"2014","unstructured":"Ding H, Liu XC, Mei Q, Xu JM, Hu XY, Hu J. Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. World J Gastroenterol. 2014, 20:3716-8. 10.3748\/wjg.v20.i13.3716","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1600715","article-title":"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis","volume":"54","author":"Rodr\u00edguez-Lago I","year":"2019","unstructured":"Rodr\u00edguez-Lago I, Sempere L, Guti\u00e9rrez A, et al.. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol. 2019, 54:459-64. 10.1080\/00365521.2019.1600715","journal-title":"Scand J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21746","article-title":"The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis?","volume":"34","author":"Rodr\u00edguez-Lago I","year":"2019","unstructured":"Rodr\u00edguez-Lago I, Ben\u00edtez JM, Sempere L, S\u00e1ez-Gonz\u00e1lez E, Barreiro-de Acosta M, de Z\u00e1rate JO, Cabriada JL. The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis?. J Clin Apher. 2019, 34:680-5. 10.1002\/jca.21746","journal-title":"J Clin Apher"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.01.124","article-title":"Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-\u03b1 drug failure","volume":"50","author":"S\u00e1ez-Gonz\u00e1lez E","year":"2018","unstructured":"S\u00e1ez-Gonz\u00e1lez E, Aguas M, Huguet JM, Nos P, Beltr\u00e1n B. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-\u03b1 drug failure. Dig Liver Dis. 2018, 50:415-7. 10.1016\/j.dld.2018.01.124","journal-title":"Dig Liver Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.12.030","article-title":"Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte\/monocyte apheresis: a case series","volume":"103","author":"Yokoyama Y","year":"2018","unstructured":"Yokoyama Y, Kamikozuru K, Watanabe K, Nakamura S. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte\/monocyte apheresis: a case series. Cytokine. 2018, 103:25-8. 10.1016\/j.cyto.2017.12.030","journal-title":"Cytokine"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jca.1000","article-title":"Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study","volume":"16","author":"Shimoyama T","year":"2001","unstructured":"Shimoyama T, Sawada K, Hiwatashi N, et al.. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001, 16:1-9. 10.1002\/jca.1000","journal-title":"J Clin Apher"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4037","article-title":"Combination therapy with tofacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction therapy for refractory ulcerative colitis","volume":"12","author":"Tanida S","year":"2020","unstructured":"Tanida S, Ozeki K, Mizoshita T, et al.. Combination therapy with tofacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction therapy for refractory ulcerative colitis. J Clin Med Res. 2020, 12:36-40. 10.14740\/jocmr4037","journal-title":"J Clin Med Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i29.9699","article-title":"Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs","volume":"20","author":"Saniabadi AR","year":"2014","unstructured":"Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol. 2014, 20:9699-715. 10.3748\/wjg.v20.i29.9699","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5302-20","article-title":"Refractory ulcerative colitis improved by scheduled combination therapy of vedolizmab and granulocyte and monocyte adsorptive apheresis","volume":"59","author":"Nakamura M","year":"2020","unstructured":"Nakamura M, Yamamura T, Maeda K, et al.. Refractory ulcerative colitis improved by scheduled combination therapy of vedolizmab and granulocyte and monocyte adsorptive apheresis. Intern Med. 2020, 59:3009-14. 10.2169\/internalmedicine.5302-20","journal-title":"Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2333w","article-title":"Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis","volume":"7","author":"Tanida S","year":"2015","unstructured":"Tanida S, Mizoshita T, Nishie H, et al.. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. J Clin Med Res. 2015, 7:884-9. 10.14740\/jocmr2333w","journal-title":"J Clin Med Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335401-successful-treatment-of-refractory-ulcerative-colitis-with-5-aminosalicylic-acid-intolerance-and-biologic-therapy-resistance-using-combined-granulocyte-and-monocyte-adsorptive-apheresis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:12:59Z","timestamp":1737267179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335401-successful-treatment-of-refractory-ulcerative-colitis-with-5-aminosalicylic-acid-intolerance-and-biologic-therapy-resistance-using-combined-granulocyte-and-monocyte-adsorptive-apheresis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.77641","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}